Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Boudreau

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
Brain Research|March 24, 2010
RNAi therapeutics for CNS disordersRyan L Boudreau, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 13, 2008
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivoRyan L Boudreau, Inês Martins, Beverly L Davidson
Human Molecular Genetics|April 5, 2011
RNAi medicine for the brain: progresses and challengesRyan L Boudreau, Edgardo Rodríguez-Lebrón, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2011
Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's diseaseRyan L Boudreau, Ryan M Spengler, Beverly L Davidson
The American Journal of Pathology|June 1, 1981
Proteoglycans in the microvasculature. I. Histochemical localization in microvessels of the rabbit eyeD H Ausprunk, C L Boudreau, D A Nelson
The American Journal of Pathology|June 1, 1981
Proteoglycans in the microvascular. II. Histochemical localization in proliferating capillaries of the rabbit corneaD H Ausprunk, C L Boudreau, D A Nelson
Cell Metabolism|March 12, 2024
Fndc5 is translated from an upstream ATG start codon and cleaved to produce irisin myokine precursor protein in humans and miceNathan H Witmer, Connor R Linzer, Ryan L Boudreau
RNA (New York, N.Y.)|August 14, 2008
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAsRyan L Boudreau, Alex Mas Monteys, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2014
Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapyMegan S Keiser, Ryan L Boudreau, Beverly L Davidson
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 1, 1979
The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid depositionR Kisilevsky, M D Benson, M A Axelrad, et al.
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
Brain Research|March 24, 2010
RNAi therapeutics for CNS disordersRyan L Boudreau, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 13, 2008
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivoRyan L Boudreau, Inês Martins, Beverly L Davidson
Human Molecular Genetics|April 5, 2011
RNAi medicine for the brain: progresses and challengesRyan L Boudreau, Edgardo Rodríguez-Lebrón, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2011
Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's diseaseRyan L Boudreau, Ryan M Spengler, Beverly L Davidson
The American Journal of Pathology|June 1, 1981
Proteoglycans in the microvasculature. I. Histochemical localization in microvessels of the rabbit eyeD H Ausprunk, C L Boudreau, D A Nelson
The American Journal of Pathology|June 1, 1981
Proteoglycans in the microvascular. II. Histochemical localization in proliferating capillaries of the rabbit corneaD H Ausprunk, C L Boudreau, D A Nelson
Cell Metabolism|March 12, 2024
Fndc5 is translated from an upstream ATG start codon and cleaved to produce irisin myokine precursor protein in humans and miceNathan H Witmer, Connor R Linzer, Ryan L Boudreau
RNA (New York, N.Y.)|August 14, 2008
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAsRyan L Boudreau, Alex Mas Monteys, Beverly L Davidson
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2014
Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapyMegan S Keiser, Ryan L Boudreau, Beverly L Davidson
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 1, 1979
The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid depositionR Kisilevsky, M D Benson, M A Axelrad, et al.
Pageof 8